Selected article for: "fusion protein and protein domain"
Author: Eric W. Stawiski; Devan Diwanji; Kushal Suryamohan; Ravi Gupta; Frederic A. Fellouse; J. Fah Sathirapongsasuti; Jiang Liu; Ying-Ping Jiang; Aakrosh Ratan; Monika Mis; Devi Santhosh; Sneha Somasekar; Sangeetha Mohan; Sameer Phalke; Boney Kuriakose; Aju Antony; Jagath R. Junutula; Stephan C. Schuster; Natalia Jura; Somasekar Seshagiri
Title: Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility
  • Document date: 2020_4_10
    • ID: jfdshwfh_33
    Snippet: Currently, there are no approved therapeutics for treating or preventing COVID-19 caused by the SARS-CoV-2. Therefore, development of therapeutics to treat patients and mitigate the COVID-19 pandemic is urgently needed (Cascella et al., 2020; Jiang, 2020) . Several small molecules and neutralizing antibodies for treatment are in development (Li and De Clercq, 2020; Zhou et al., 2020b) . Soluble ACE2 and ACE2-Fc fusion protein have been proposed a.....
    Document: Currently, there are no approved therapeutics for treating or preventing COVID-19 caused by the SARS-CoV-2. Therefore, development of therapeutics to treat patients and mitigate the COVID-19 pandemic is urgently needed (Cascella et al., 2020; Jiang, 2020) . Several small molecules and neutralizing antibodies for treatment are in development (Li and De Clercq, 2020; Zhou et al., 2020b) . Soluble ACE2 and ACE2-Fc fusion protein have been proposed as decoy SARS-CoV-2 receptor therapeutic (Hofmann et al., 2004; Kruse, 2020; Lei et al., 2020) . Soluble ACE2, as a therapy for pulmonary arterial hypertension, has been shown to be safe in early in-human clinical studies (Guignabert et al., 2018; Haschke et al., 2013) . A rationally designed, catalytically inactive, human ACE2 that carries one or more of the natural variants predicted to show improved binding to SARS viral S-protein RBD could be safely developed as a soluble protein with or without an Fc domain for treatment of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • approved therapeutic and fusion protein: 1, 2, 3
    • approved therapeutic and prevent treat: 1, 2, 3
    • approved therapeutic and prevent treat approved therapeutic: 1
    • arterial hypertension and clinical study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • arterial hypertension and prevent treat: 1
    • arterial hypertension and pulmonary arterial hypertension: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • arterial hypertension and pulmonary arterial hypertension therapy: 1, 2, 3, 4, 5
    • clinical study and fusion protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • clinical study and human clinical study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical study and patient treat: 1, 2, 3, 4
    • clinical study and prevent treat: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • clinical study and pulmonary arterial hypertension: 1, 2, 3, 4, 5, 6, 7
    • decoy SARS receptor and fusion protein: 1
    • Fc domain and fusion protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • Fc domain and prevent treat: 1
    • fusion protein and patient treat: 1, 2
    • fusion protein and prevent treat: 1, 2, 3, 4, 5, 6, 7, 8
    • human clinical study and patient treat: 1
    • human clinical study and prevent treat: 1